ALEXANDRIA, Va., Nov. 6 -- United States Patent no. 12,459,958, issued on Nov. 4, was assigned to BeOne Medicines I GmbH (Basel, Switzerland).
"Tricyclic compounds as HPK1 inhibitor and the use thereof" was invented by Jing Li (Beijing), Zhiwei Wang (Beijing) and Sanjia Xu (Beijing).
According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed herein is a tricyclic compound of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein."
The patent was filed on July 17, 2020, under Application No. 17/627,885.
*For further i...